Published on
December 25, 2021
- 19:56 GMT
LATAM Pharma welcomes the phase III results of CanSino’s AD5-nCOV vaccine, published at The Lancet
ZUG, ZUG, SWITZERLAND, December 25, 2021 /EINPresswire.com/ -- LATAM Pharma Innovative Ventures AG, Swiss company in charge of commercializing Convidecia™, the single AD5-nCOV dose vaccine for COVID-19 from CanSino Biologics Inc., salutes the publication …
Distribution channels:
Business & Economy, Culture, Society & Lifestyle
...
